Disadvantages of Structured Treatment Interruption Persist in Patients With Multidrug-Resistant HIV-1

Department of Medicine, Positive Health Program, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA.
JAIDS Journal of Acquired Immune Deficiency Syndromes (Impact Factor: 4.56). 11/2006; 43(2):169-78. DOI: 10.1097/01.qai.0000242450.74779.ee
Source: PubMed


We report the final results of Community Programs for Clinical Research on AIDS (CPCRA-064) study, a multicenter, prospective, randomized, controlled trial that determines the long-term clinical impact of structured treatment interruption (STI) in patients with multidrug-resistant (MDR) HIV-1.
Two hundred seventy-four patients on stable antiretroviral therapy with MDR HIV-1 treatment failure were randomized to a 4-month STI, followed by an optimized antiretroviral regimen (STI arm, n = 140) or an immediate change to an optimized antiretroviral regimen (control arm, n = 134). Main outcome measures were progression of disease or death and changes from baseline in HIV RNA levels (log copies/mL) and CD4 cell counts (cells/mm). The median baseline HIV RNA level was 5.0 log copies/mL, the median CD4 count was 147 cells/mm, and the nadir CD4 count was 32 cells/mm. The median follow-up was 37 months. After the STI period, there were no differences in HIV RNA level responses between treatment arms. Differences in CD4 count responses always favored the control arm, with an advantage of 84 cells from 0 to 4 months (P < 0.0001), 50 cells from 4 to 12 months (P < 0.0001), 45 cells from 12 to 24 months (P = 0.006), and 43 cells after 24 months (P = 0.07). Rates in the STI and control arms for first progression-of-disease event or death were 17.5 and 14.3, respectively (hazard ratio = 1.28; P = 0.22).
STI before changing regimens in patients with MDR HIV-1 treatment failure has a prolonged negative impact on CD4 cell count recovery and does not confer progression of disease or virologic benefits.

Download full-text


Available from: Douglas Mayers
  • Source
    • "Another strategy was to promote reemergence of drug-susceptible virus using structured treatment interruptions and thereby to enhance virologic response to subsequent antiretroviral therapy [9]. This strategy was abandoned when it was proven to be ineffective in promoting sustained virologic suppression or disease control and, more alarmingly, was associated with protracted CD4 declines [10]. A more successful treatment strategy was the use of multiple drug rescue therapy, also called mega-HAART or giga-HAART, whereby patients were treated with as many partially active agents as possible, generally six to eight [11–13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the early years of the highly active antiretroviral therapy (HAART) era, HIV with resistance to two or more agents in different antiretroviral classes posed a significant clinical challenge. Multidrug-resistant (MDR) HIV was an important cause of treatment failure, morbidity, and mortality. Treatment options at the time were limited; multiple drug regimens with or without enfuvirtide were used with some success but proved to be difficult to sustain for reasons of tolerability, toxicity, and cost. Starting in 2006, data began to emerge supporting the use of new drugs from the original antiretroviral classes (tipranavir, darunavir, and etravirine) and drugs from new classes (raltegravir and maraviroc) for the treatment of MDR HIV. Their availability has enabled patients with MDR HIV to achieve full and durable viral suppression with more compact and cost-effective regimens including at least two and often three fully active agents. The emergence of drug-resistant HIV is expected to continue to become less frequent in the future, driven by improvements in the convenience, tolerability, efficacy, and durability of first-line HAART regimens. To continue this trend, the optimal rollout of HAART in both rich and resource-limited settings will require careful planning and strategic use of antiretroviral drugs and monitoring technologies.
    Full-text · Article · Nov 2012 · AIDS research and treatment
  • Source
    • "The CPCRA 064 study found that there was an increased risk of death, a long-term negative effect on CD4+ cell count, and no virologic or clinical benefit associated with a structured treatment interruption.(Lawrence, et al., 2006) Based on these, it is advised to not discontinue an ARV regimen in an adherent patient except for in the presence of drug resistance and when awaiting genotype results."

    Full-text · Chapter · Nov 2011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interest in therapeutic drug monitoring (TDM) as an adjunct in the management of HIV infection has increased in recent years. The protease inhibitors (PIs) have stimulated the most interest in TDM as they have considerable inter- and intra-individual variability in plasma levels and marked potential for drug interactions that may lead to reduced or elevated PI plasma concentrations. (1) There may also be a role for TDM with non-nucleoside reverse transcriptase inhibitors (NNRTIs), although this practice is not well established. TDM is currently not appropriate for nucleoside analogue reverse transcriptase inhibitors (NRTIs) as NRTIs require intracellular phosphorylation to achieve their active form, and there is only a weak correlation between plasma concentrations
    No preview · Article · Oct 2011
Show more